Filgrastim
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Filgrastim: From Neutropenia to Primary Release Disorder of Platelets
One-Sentence Summary
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF), an established treatment for reducing the duration and severity of neutropenia and for mobilising peripheral blood stem cells. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but this direction is currently supported by only 1 indirectly related publication and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Neutropenia / peripheral blood stem cell mobilisation (established use of G-CSF; no UK licence record is present in this evidence pack) |
| Predicted New Indication | Primary Release Disorder of Platelets |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, filgrastim is a recombinant G-CSF that stimulates proliferation and differentiation of the granulocyte lineage and mobilises haematopoietic stem cells into peripheral blood — it does not act on the platelet dense/alpha-granule release pathway that defines “primary release disorder of platelets” (a platelet secretion/storage-pool type disorder).
The single supporting publication is a cohort study of peripheral blood stem cell mobilisation in healthy donors, which incidentally notes that G-CSF perturbs blood cell subsets (including platelets) as a known side effect — it is not a therapeutic study of any platelet-release disorder. The high TxGNN score most likely reflects embedding proximity between “hematopoietic/bone marrow”-related disease nodes in the knowledge graph, rather than a genuine pharmacological link.
Across all ten TxGNN-predicted indications for filgrastim in this evidence pack (all platelet- or coagulation-related disorders), the pipeline’s own rationale consistently flags absent or contradictory mechanistic support, and where clinical trials do appear (e.g. Scott syndrome, platelet-type bleeding disorder), they are haematopoietic stem cell transplantation or oncology trials in which G-CSF is used incidentally as a mobilisation/supportive agent — not as a treatment for the predicted disease itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29770133 | 2018 | Cohort | Frontiers in Immunology | Study of G-CSF-mediated peripheral blood stem cell mobilisation in healthy donors; notes preferential mobilisation of lymphocyte subsets. Does not investigate a platelet release disorder as a treatment target — relevance is indirect (G-CSF’s known effect on blood cell subsets). |
UK Market Information
No UK marketing authorisation is recorded for filgrastim in this evidence pack (market status: not marketed; 0 licences on file).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no completed clinical trial and only one indirectly relevant, non-therapeutic publication supporting use of filgrastim in primary release disorder of platelets. The proposed mechanistic link is weak — G-CSF acts on granulocyte production and stem cell mobilisation, not the platelet granule-release pathway implicated in this disease — and the pipeline’s own analysis attributes the high TxGNN score to knowledge-graph embedding proximity rather than pharmacological plausibility.
To proceed, the following is needed:
- A verified UK/MHRA licence record and SmPC for filgrastim (this evidence pack has none)
- Confirmed mechanism of action data linking G-CSF to platelet granule release or storage-pool function
- Preclinical or case-level evidence specifically studying filgrastim in platelet release disorders, rather than incidental trial overlap from unrelated haematopoietic stem cell transplant/oncology studies
- Full safety/contraindication data (key warnings, contraindications, DDI), currently unavailable in this pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.